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Drug nanoparticleformulationusing ascorbicacid derivatives and its therapeutic uses have recently been introduced. Hydrophilic
ascorbic acid derivatives such as ascorbyl glycoside have been used not only as antioxidants but also as food and pharmaceutical
excipients. In addition to drug solubilization, drug nanoparticle formation was observed using ascorbyl glycoside. Hydrophobic
ascorbicacidderivativessuchasascorbylmono-anddi-n-alkylfattyacidderivativesareusedeitherasdrugsorcarriercomponents.
Ascorbyln-alkylfattyacidderivatives havebeen formulatedasantioxidantsoranticancerdrugs fornanoparticleformulationssuch
as micelles, microemulsions, and liposomes. ASC-P vesicles called aspasomes are submicron-sized particles that can encapsulate
hydrophilic drugs. Several transdermal and injectable formulations of ascorbyl n-alkyl fatty acid derivatives were used, including
ascorbyl palmitate.
1.Introduction
Antioxidants protect living systems against lipid peroxida-
tion. Vitamin E (tocopherol) and vitamin C (ascorbic acid)
are well-known lipophilic and hydrophilic chain-breaking
antioxidants, respectively [1]. Because antioxidant activity
in homogeneous solutions may not be the same as that in
heterogeneous solutions, the antioxidant properties of het-
erogeneoussolutionsincludingaggregated systems(micelles,
liposomes, and microemulsions) have been investigated.
Variation of biomembrane microenvironments may turn
vitamin E into a pro-oxidant agent [2].
Ascorbic acid contains hydroxyl groups in positions 2
(pKa:11.6), 3 (pKa :4.2), 5 (secondary alcoholic residue),
and 6 (primary alcoholic residue) (Figure 1). Ascorbic
acid is an ineﬀective antioxidant for lipid peroxidation in
hydrophobic phases, but it works very eﬃciently in aqueous
media [2]. Structural modiﬁcation of position 2, 3, 5, or 6 of
the ascorbic acid ring contributes not only to its stabilization
as an antioxidant but also to the formulation of a variety
of pharmaceutical and cosmetic products with antioxidant
activity.
Ascorbic acid derivatives can retain the same activity
exhibited by ascorbic acid. For example, the antioxidant
activity of O-substituted ascorbic acid derivatives at the
C-2 position—ascorbic acid 2-glucoside, ascorbic acid 2-
phosphate, and ascorbic acid 2-sulfate—was investigated by
Takebayashi et al. [3]. The radical-scavenging proﬁles of
ascorbic acid derivatives were closer to those of uric acid and
glutathione than to that of ascorbic acid. These data suggest
the potential usage of ascorbic acid derivatives as radical
scavengers.
Hydrophobic ascorbic acid derivatives, in which one
or more hydrocarbon chains are attached to the ascorbic
acid ring, retain the activity displayed by ascorbic acid. The
antioxidant activity of various 6-O-alkanoyl-ascorbic acids
is much better than that of ascorbic acid and tocopherols
both in vivo and in vitro [1]. The role of longer alkyl chains
in facilitating the insertion of ascorbic acid derivatives into
the cellular bilayer broadens its use to nonaqueous media.
The addition ofhydrocarbon chains (e.g.,ethersand estersat
positions 2, 3, 5, or 6 of the ascorbic acid ring) results in the
formation of amphiphilic structures in which ascorbic acid
can produce self-assembled supramolecular aggregates such
as micelles and vesicles.
In this paper, drug nanoparticle formulation using
ascorbic acid derivatives is introduced. Hydrophilic ascorbic
acid derivatives have been used not only as antioxidants but2 Journal of Drug Delivery
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Figure 1: Chemical structures of ascorbic acid and its derivatives: (a) ascorbic acid (ASA), (b) ascorbyl-2-glucoside (ASC-G), (c) ascorbyl-
6-octanoate (ASC-8), (d) ascorbyl-6-palmitate (ASC-P), (e) ascorbyl-6-stearate (ASC-S), and (f) ascorbyl-2,6-dipalmitate (ASC-DP).
also as food or pharmaceutical excipients [4, 5]. They are
usually loaded into a nanoparticle formulation to prevent
oxidation of the drugs and the components [4, 6]. Ascorbyl
n-alkyl fatty acid derivatives have been well investigated as
antioxidants for nanoparticle formulations, such as micelles,
microemulsions, and liposomes. Physicochemical properties
of ascorbic acid derivatives described in the paper and their
applications are summarized in Tables 1 and 2, respectively.
Ascorbyl-2-glucoside and ascorbyl palmitate have been well
investigated among the derivatives. Physicochemical prop-
erty, especially, solubility of ascorbyl acid derivatives was
apparently changed not only by the substitution of alkyl
chains but also by the chain length. Several papers have
described ascorbic acid derivatives including the currentJournal of Drug Delivery 3
methods of synthesis [7], so we hereby focused on the
nanoparticle formulations themselves.
1.1. Ascorbyl-2-Glucoside (ASC-G). As a 2-O-substituted
ascorbic acid, ASC-G was used as not only a solubilizer but
also as an additive for nanoparticle formation. ASC-G has
2 beneﬁcial properties: high stability against thermal and
oxidative degradation and rapid conversion to ascorbic acid
by α-glucosidase in blood and liver cells [8, 9]. ASC-G is a
newly developed food additive. Moreover, it is expected to
be used in the development of lipid-soluble vitamins and as
the principal component in cosmetic ingredients [10]. Inoue
et al. reported solubilization and nanoparticle formation of
clarithromycin (CAM) using ASC-G [11]. We used ascorbic
acid as a solubilizing agent because it can solubilize CAM;
however, photodecomposition of ascorbic acid was observed
in aqueous media. To avoid photodecomposition, ASC-G
was used instead of ascorbic acid to improve the dissolution
characteristics of CAM (Figure 2). Cogrinding of CAM with
A S C - Ga tam o l a rr a t i oo f1:1o rl e s sw a sa ne ﬀective way
to improve CAM solubility in aqueous solution. Molecular
interaction between the N,N-dimethyl group of CAM and
the hydroxyl group of ASC-G in aqueous solution was
observedby 1Ha n d13C nuclear magnetic resonance (NMR).
In addition to solubilization, CAM nanoparticle formation
w a so b s e r v e dw h e na2 : 1g r o u n dm i x t u r eo fC A Ma n d
ASC-G was dispersed into an aqueous media. This molar
ratio-speciﬁc nanoparticle formation might be attributable
to a grinding-induced interaction in the solid state via the
ketonegroup in thelactonering ofCAM.Itis concludedthat
cogrindingwithASC-Gisapromisingmethodformodifying
thedissolutionpropertiesofCAM.Furtherstudyfocusingon
theapplicationofASC-Ginotherpoorlywater-solubledrugs
is required.
1.2.Ascorbyln-Alkyl FattyAcidDerivative: StructureandOxi-
dation Process. Ascorbyl monoalkylate has both lipophilic
and hydrophilic moiety and exhibits properties of typical
surfactant. The structures and physicochemical properties
have been well described by Palma et al. [12]. The self-
assembly properties depend on the length of the n-alkyl fatty
chain. Ascorbyl monoalkylate starts to aggregate at the Kraﬀt
point, at which the solubility reaches the critical micellar
concentration (CMC). Above this temperature, ascorbyl
monoalkylate can aggregate in micelles or the gel phase,
depending on the alkyl side chain. Upon cooling, liquid-
crystal structures (coagels) are obtained for less soluble
derivatives(ascorbyllaurate,ascorbylmyristate, andascorbyl
palmitate). These structures can solubilize drugs, improve
their stability, and promote their permeation through the
skin. Their rheological properties are also suitable for topical
administration of pharmaceuticals.
Reducing activity (RA) measurement of some antiox-
idant chemicals indicated that hydrophobic vitamin C
derivatives (from ascorbyl octanoate to ascorbyl stearate)
keep the same antioxidant activity of vitamin C but have the
advantage ofbeing solublein bothaqueousand hydrophobic
media [1]. These derivatives possess the same RA of several
(e)
(d)
(c)
(b)
(a)
0 2 04 06 08 0 1 0 0
(%)
Solubilization
Particles (< 0.8μm)
Particles (> 0.8μm)
(A)
0
0.2
0.4
0.6
0.8
1
S
i
z
e
(
μ
m
)
0 24 48 72 96 120 144 168
Time (h)
GM (CAM:ASC-G = 2:1)
GM (CAM:ASA = 2:1)
(B)
Figure2:Comparisonofsolubilizationandnanoparticleformation
characteristics between the CAM-ascorbic acid (ASA) and CAM-
ASC-Gsystems.(A)ParticlefractionsofthedrugintheCAM:ASC-
G systems. (B) Changes in the mean particle size of CAM ﬁne
particles after storage: (a) Unprocessed CAM, (b) PM (CAM:ASC-
G = 2:1),(c)GM(CAM:ASC-G= 2:1),(d)PM(CAM:ASA=
2:1),and(e)GM(CAM:ASA= 2:1).
natural products; therefore, they can be used as radical
scavengers in the protection of such natural compounds.
The enediol functionality of ascorbyl palmitate is prone to
oxidation in the presence of oxygen, a process that usually
leads to formation of dehydroascorbyl palmitate (Figure 3)
in which the OH functionality is oxidized into keto moiety
[13–15].
1.3. Ascorbyl Octanoate (ASC-8). The self-assembling and
antioxidant activities of ASC-8 were reported by LoNostro
et al. [1]. ASC-8 formed homogeneous micelles in pH 2
aqueous solution at 25◦C (nonionic form), exhibiting nearly
spherical aggregates as revealed by viscosity, dynamic light
scattering (DLS),and small-angle neutronscattering (SANS)
experiments. The critical micelle concentration was 6mM4 Journal of Drug Delivery
Table 1: Physicochemical properties of ascorbic acid derivatives.
Ref
ASC-G
Solubility 714g/L at 19 ± 1◦C ∗
Surface tension 71mN/m (0.99mg/mL) ∗
Stability Half-life at 50◦C: >1y e a ra tp H4 ,7 ,a n d9 ∗
Toxicity Acute oral toxicity (LD50): 2500mg/kg (Rat) ∗
Acute dermal toxicity (LD50): >2000mg/kg (Rat)
ASC-8
Critical micelle concentration 6 × 10−3 mol/L (pH2) [1]
Hydrodynamic radius 25.4 ˚ A[ 1]
Head group area 57.6 ˚ A2 [1]
Aggregation number 84 [1]
ASC-P
Solubility 5.6mg/mL at 25 ± 0.1◦C ∗∗
Toxicity Acute oral toxicity (LD50): 25000mg/kg (Mouse) ∗∗
Acute dermal toxicity (LD50): >3000mg/kg (Guinea pig)
ASC-S
Solubility Insoluble in water, soluble in ethanol ∗∗∗
ASC-DP
Solubility Insoluble in water ∗∗∗∗
Stability Stable in aqueous media at pH 4, 7, and 10 ∗∗∗∗
Stable in methanol ∗∗∗∗
Safety Oral administration:up to 1.25mg/kg body weight daily ∗∗∗∗∗
∗2-O-α-D-glucopyranosyl-L-ascorbic acid, Full Public Report National Industrial ChemicalsNotiﬁcation and AssessmentScheme, ﬁle no. STD/1056, 2003.
∗∗http://www.sciencelab.com/xMSDS-Ascorbyl palmitate-9922973.
∗∗∗http://www.fao.org/ag/agn/jecfa-additives/details.html?id=43.
∗∗∗∗Unpublished data.
∗∗∗∗∗http://www.hc-sc.gc.ca/.
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Figure 3: Tautomerization of ascorbyl palmitate. Structure of
dehydroascorbyl palmitate is shown in parentheses.
(surface tension), with a hydrodynamic radius of 30 ˚ A( l i g h t
scattering) and 25.4 ˚ A (SANS), area per molecule of about
57.6 ˚ A, and aggregation number of 84.
SolubilizationofdrugsinASC-8micellardispersions was
reported by Palma et al. [16]. Solubilization of drugs was
performed above the CMC and Kraﬀt temperature deter-
mined by surface tension and conductivity measurements.
The solubility of hydrophobic drugs, such as phenacetin,
danthron, anthralin, and retinoic acid, was greatly enhanced
by the solubilization. Furthermore, the antioxidant activity
exhibited by the ascorbate rings that form the hydrophilic
external shells in ASC-8 micellar dispersions can protect
degradable materials that have been solubilized in the
internal hydrophobic micellar core from radical-initiated
oxidation.
1.4. Encapsulation of Ascorbyl Palmitate (ASC-P) in Carriers.
ASC-P has been used as a model drug for nanosized
lipid carriers. As an antioxidant, ASC-P has been also
used in the cosmetics, food, and pharmaceutical industries.
Teeranachaideekul et al. reported the physicochemical char-
acterization and in vitro release studies of ASC-P-loaded
nanostructured lipid carriers (NLC gels) [17, 18]. NLC gels
were prepared by a high-pressure homogenization technique
using oil Labraﬁl M1944 and solid lipids such as cetyl
alcohol (CA),Imwitor 900(GMS), and nonionic hydrophilic
white beeswax (BW). Nanosized particles <250nm withJournal of Drug Delivery 5
low polydispersity indices were prepared although micro-
scopic observation indicated that the nanoparticles were
nonspherical. The encapsulation eﬃciency of ASC-P was
almost 100%, and its zeta potential was less than −30mV.
Diﬀerential scanning calorimetry (DSC) and powder X-
ray diﬀraction (PXRD) measurements indicated that the
lipid in each formulation was recrystallized in the solid
state, possessing a less-ordered structure compared to that
of the bulk material. The release study of ASC-P from
each formulation using Franz diﬀusion cells revealed that
the lipid matrix type aﬀects both the rate and the release
pattern. The release rate was in the order of ASC-P-
loaded BW > ASC-P-loaded GMS > ASC-P-loaded CA.
In viscoelastic analysis, all formulations showed that the
storage modulus (G
 ) was higher than the loss modulus
(G
  ) and that the phase angle was <45◦, indicating that
they possess more elastic than viscous properties. Thus,
NLC gel can be used as a colloidal carrier for topical appli-
cation.
Wittayasuporn et al. reported encapsulation of ASC-
P into methyl ether-terminated poly(ethylene oxide)-4-
methoxycinnamolyphthaloylchitosan (PCPLC) nanoparti-
cles [19]. PCPLC is a UV-screening amphiphilic chitosan
derivative and is able to self-assemble into nanoparticles.
Encapsulation of ASC-P into PCPLC resulted in 689nm
particleswith encapsulationeﬃciencyof84%ata56% drug-
loading rate. The encapsulated ASC-P showed signiﬁcantly
improved stability when examined by the 1HN M Rm e t h o d
in which both the tautomerized and the oxidized ASC-P
could be monitored. ASC-P-encapsulated PCPLC nanopar-
ticles demonstrated no short-term cytotoxicity against the
human skin melanoma A-375 cell line and no short-
term skin irritation on human volunteers. Aqueous sus-
pension of PCPLC nanoparticles successfully inhibited the
growth of Escherichia coli ATCC 25922 and Staphylococcus
aureus ATCC 25923. Thus, ASC-P-encapsulated PCPLC
nanoparticles with a photoprotective property appeared to
be applicable to topically applied photolabile drugs and
cosmetics.
Yoksan et al. reported the encapsulation of ASC-P in
chitosan particles by oil-in-water (o/w) emulsion and ionic
gelation processes using sodium triphosphate pentabasic
(TPP) as a cross-linking agent [20]. ASC-P encapsulation
was conﬁrmed using conventional evaluation instruments:
Fourier-transform infrared (FT-IR), ultraviolet-visible (UV-
vis) spectrophotometer, thermal gravimetric analysis, and
PXRD. The morphology of ASC-P-loaded chitosan particles
was spherical with an average size of 60–100nm as observed
by scanning electron microscopy (SEM) and 30–60nm
by transmission electron microscopy (TEM). The loading
capacity (weight of loaded ASC-P/weight of sample) and
encapsulation eﬃciency (weight of loaded ASC-P/weight of
initial ASC-P) of ASC-P in the nanoparticles were about
8–20% and 39–77%, respectively, when the initial ASC-
P concentration was in the range of 25–150% (w/w) of
chitosan. Release of ASC-P from the nanoparticles was
explained by the loss of the cross-linked structure via elec-
trostatic interaction between ammonium ions on chitosan
chains and phosphoric groups of TPP molecules due to the
deprotonation of chitosan in Tris buﬀer (pH ∼ 8).
1.5. Stability of ASC-P in Carriers. ASC-P is a promising
antioxidant candidate; however, its practical use is restricted
becauseofitsoxidation-inducedpoorsolubilityandinstabil-
ity. Kristl et al. reported that the stabilizing eﬀect of carrier
systems for ASC-P was investigated using microemulsions
(ME), liposomes, and solid lipid nanoparticles (SLNs) [14].
ASC-P was resistant against oxidation in the order of
nonhydrogenated soybean lecithin liposomes, SLN, w/o and
o/w ME, and hydrogenated soybean lecithin liposomes.
The location of the nitroxide group of ASC-P in a carrier
system is crucial to its stability. ¨ Uner et al. compared
the stability of ASC-P loaded in SLN, nanostructured
lipid carriers (NLCs), and nanoemulsions (NEs) [15]. The
highest level of degradation was observed with NE at all
storage temperatures. These results indicated that the carrier
structure is important to the maintenance of ASC-Pstability.
The degree of skin moisturizing and penetration of ASC-
P entrapped in SLN, NLC, and NE incorporated into
hydrogel was signiﬁcantly higher compared to that of NE
[21]. Enhanced stability of ASC-P encapsulated in poly(D,L-
lactide) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA)
nanoparticles was reported by Tangsumranjit et al. [22].
In ASC-P-encapsulated PLA nanoparticles, ionic strength,
and the degassing step aﬀected ASC-P stability. Use of the
PLA nanoparticle is a promising formulation for ASC-P
stabilization.
1.6.ASC-P Nanosuspension. Teeranachaideekul etal.investi-
gated the feasibility of applying nanosuspension technology
by high-pressure homogenization (DissoCubes technology)
to enhance the chemical stability of ASC-P, followed by
lyophilization[23].Sodiumdodecylsulfate(SDS)andTween
80 were used as emulsifying agents to stabilize the devel-
oped ASC-P nanosuspensions. Tween 80 more eﬀectively
stabilized the nanoparticles than SDS. The percentage of
ASC-P remaining in the nanosuspensions stabilized with
Tween 80 was >90% after 3-month storage at 4◦C, 25◦C, and
40◦C.ThemeansizeoftheASC-Pnanosuspensions prepared
by redispersion of the lyophilized product was signiﬁcantly
higher compared with the system using 2–10% trehalose
as a cryoprotectant. DissoCubes technology appeared to be
eﬀective in preparation of ASC-P nanoparticles using the
optimum formulation.
1.7. Therapeutic Uses of Ascorbyl n-Alkyl Fatty Acid De-
rivative-Incorporated Nanocarriers. Representative applica-
tions of ASC-P for therapeutic uses include the skin
permeation enhancer and synergistic cytotoxic action. Skin
permeation enhancement of ASC-P by liposomal hydrogel
(lipogel) formulation was reported by Lee et al. [24]. The
ASC-P-incorporated liposome was formulated as lipogel
by dispersion of the liposome into a poloxamer hydrogel
matrix. The permeated amounts of ASC-P from the lipogels
were higher than that of the control hydrogel containing
Transcutol to solubilize ASC-P. Skin permeation of ASC-P6 Journal of Drug Delivery
improved when an electric current system that mimics an
electric skin massager was used. In the cathodal delivery
condition,theskin permeation characteristicsofthenegative
lipogels were superior to those obtained with the neutral
lipogels.
D’Souza et al. reported anticancer toxicity of ASC-P-
incorporated liposomes and micelles in numerous cancer
cell lines [25]. ASC-P-incorporated liposomes preferentially
associated with various cancer cells compared to non-
cancer cells. In addition, ASC-P enhanced the cytotoxic
action of paclitaxel when simultaneously incorporated into
liposomes. The tumor-cell association and killing and the
cytotoxic action of encapsulated paclitaxel in liposomes
can potentiate the eﬀect of ASC-P and paclitaxel. Cancer
cell cytotoxicity and targeting was also observed both
in vitro and in vivo using polyethylene glycol phos-
phatidylethanolamine micelles [26]. The mechanism of cell
deathwasreported tobeduetogenerationofreactiveoxygen
species.
Similarcytotoxicactivity against tumorcellswas reported
using polymeric nanoparticles containing the antitumor
compound transdehydrocrotonin (DHC) and L-ascorbic
acid 6-stearate (ASC-S), which was taken up more eas-
ily by tumor cells than by normal ones [27]. ASC-S-
DHC nanoparticles were prepared by the nanoprecipitation
method, in which PLGA, DHC, and ASC-S dissolved in
acetone were added to an aqueous solution containing
Pluronic F68 and polyvinyl alcohol (PVA). ASC-S-DHC
nanoparticles showed high drug loading eﬃciency (81–88%)
and negative zeta potential (−29 to −32mV) due to ASC-S.
DHC-loaded nanoparticles demonstrated sustained release
behavior. ASC-S-DHC nanoparticle suspension was a more
eﬀective antitumor agent than free DHC or DHC nanopar-
ticles. Apoptosis induction of an ASC-S-DHC nanoparticle
suspension was increased by the receptor-mediated path-
way.
Gopinath et al. reported on the formation, character-
ization, and applications of ASC-P vesicles (Aspasomes)
[28]. Submicron-sized Aspasomes were prepared using a
ﬁlm hydration method. A lipid ﬁlm composed of various
molar ratios of ascorbyl palmitate and cholesterol (27/63
to 72/18) and dicetyl phosphate at 10mol% of total lipid
was hydrated with phosphate buﬀered saline (PBS, pH
7.4). Aspasomes could encapsulate the hydrophilic drug
zidovudine (AZT) when the ﬁlm was hydrated with AZT-
containing PBS. The suspension was then sonicated with
an ultrasonicator for preparation of AZT-encapsulated
aspasomes. The cholesterol content of the Aspasomes was
not related with vesicle size, zeta potential, or percent of
AZT entrapment. The release rate of AZT was changed
by variation of the proportion of cholesterol, although
there was no relation between release rate and cholesterol
content. The antioxidant potency of ascorbyl moiety was
retained even after the conversion of ascorbyl palmitate
into an aspasome, and it rendered much higher antioxidant
activity than ascorbic acid. The aspasome also showed
enhanced skin permeation and retention properties of
AZT, likely due to a role of ASC-P as a permeation
enhancer.
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Figure 4: Particle size distribution patterns of ASC-DP/surfactant
(1:1 molar ratio) suspensions. The surfactants included (a) SDS,
(b) CTAB, (c) Brij78, and (d) DSPE-PEG.
1.8. Ascorbyl 2,6-Dipalmitate (ASC-DP). ASC-DP has been
used in the ﬁeld of cosmetics [29, 30]a n ds h o w se x t r e m e l y
low water solubility. In contrast with ASC-P, ASC-DP
cannot form micelles or liposomal structures on its own;
however, the ASC-DP-distearoylphosphatidylethanolamine-
polyethylene glycol 2000 (DSPE-PEG) complex forms stableJournal of Drug Delivery 7
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Figure 5: Schematic representation for proposed structure of N-4472/ASA surface active complex formation and the subsequent self-
associationused to form the stable nanosuspension.
nanoparticles (Figure 4). Moribe et al. prepared drug-
containing ASC-DP/DSPE-PEG nanoparticles and inves-
tigated their physical stability [31]. Many poorly water-
soluble drugs were incorporated into the nanoparticles.
Amphotericin B (AmB), a polyene macrolide antibiotic drug
used to treat systemic invasive fungal infection, was selected
as the model drug because it speciﬁcally interacts with
DSPE-PEG [32]. This intermolecular interaction is believed
to contribute to the eﬀectiveness of AmB incorporation
into the ASC-DP/DSPE-PEG nanoparticles. The stability,
toxicity, and blood residence of the AmB/ASC-DP/DSPE-
PEG nanoparticles was also investigated. The minimum
lethal dose of Fungizone, a formulation of AmB solubi-
lized with sodium deoxycholate, was 3.0mg/kg, while that
of AmB/ASC-DP/DSPE-PEG nanoparticles was 10.0mg/kg
in a formulation that was intravenously administered
to mice. Intravenously administered AmB/ASCDP/DSPE-
PEG nanoparticles were detected at higher concentrations
than Fungizone in plasma. Thus, the ASC-DP/DSPE-PEG
nanoparticle system appears to be a promising delivery
system for hydrophobic drugs.
2.Conclusions
Formulation of hydrophilic and hydrophobic drugs using
a nanosized carrier system is a promising way to achieve
the desired therapeutic eﬀect. Nanoparticle formation of
ascorbic acid derivatives with or without drugs is practically
applicable as transdermal and injectable formulations. The
ascorbic acid derivatives shown in this paper can possibly
be used as a model drug, a component of the carrier, or
both. Ascorbic acid derivatives have been widely used as
antioxidative drugs, the activities of which are similar to
that of ascorbic acid. When combined with other excipients,
such as oil with lipids and chitosan derivatives, several
kindsofASC-P-incorporatednanoparticleswereformulated.
Ascorbic acid and its derivatives are also used as cytotoxic
drugs against cancer cell lines. Ascorbic acid derivatives
with an alkyl chain are preferred because of the inter-
action with and insertion into the hydrophobic part of
the membrane. This combined use with anticancer drugs
incorporated in the carrier system apparently increased the
eﬃcacy.
A formulation design based on the chemical structure
of the components is required not only to prepare stable
drug nanoparticles but also to the broader application of
ascorbic acid derivatives in therapeutic uses. The inter-
molecularinteraction betweeneach componentandascorbic
acid derivatives contributes to eﬀective drug solubilization
and stabilization to enable nanoparticle formulation. For
example, aspasomes were formulated as vesicles composed
of various components that interacted with each other
[28]. Furthermore, the complex formation between the
hydrophobic drug N-4472 and ascorbic acid and the sub-
sequent self-association contributed to form the colloidal
particles in aqueous solution (Figure 5)[ 33]. A novel drug
delivery carrier system using ascorbic acid derivatives is
going to be developed using this chemical structure-based
design.
Physicochemical characterization of the colloidal par-
ticles is important for understanding the drug absorption
mechanism and therapeutic eﬃcacy, although it is not easy.
The molecular mobility measurement of a drug in aqueous
media using NMR is useful to evaluate the molecular states
of the drug in the formulation as well as in the dispersing
media. This mechanistic study revealed the role of ascorbic
acid derivatives in vitro and in vivo.8 Journal of Drug Delivery
Table 2: Application of ascorbic acid derivatives.
Ref
ASC-G
Quasidrug principal ingredient in skin care products [3]
Food additive [3]
Medical additive in commercial cosmetics [3]
Skin antioxidant [10]
Prevention of sinusoidal endothelial cell apotosis in preserved graft [10]
High stability against thermal and oxidative degradation [9]
Rapid conversion to ascorbic acid by α-glucosidase in the blood [10]
Solubilization of clarithromycin (CAM) [11]
Nanoparticle formationof CAM [11]
Stabilization of CAM nanosuspension [11]
ASC-8
Solubilizationof phenacetin, danthron, anthralin, and retinoic acid [12]
Solubilization capacity of anthralin: ASC-8 < −10 < −12 < −14 < −16 [12]
ASC-P
Cosmetic ingredients [5]
Solubilization of drug [5]
Decrease viscosity of gel formulation [5]
Skin moisturizingand penetration eﬀect of ASC-P entrapped in SLN, NLC, and NE incorporated into hydrogel [21]
Antioxidant [17–20, 23]
Stabilization of ASC-P by encapsulation in PLA nanoparticles [22]
Skin permeation enhancer [24]
Cytotoxicity against cancer cell [25, 26]
ASC-P vesicles (Aspasomes) [28]
ASC-S
Cosmetic ingredients ∗
Cytotoxicity against cancer cell [27]
ASC-DP
Cosmetic ingredients ∗
Antioxidant (skin whitening action) [29]
Extended the stability of adhesive transdermal pharmaceuticals [29]
Nanoparticle formation with DSPE-PEG [31]
Drug encapsulation in ASC-DP/DSPE-PEG [31]
∗Final report on the safetyassessment of ascorbyl palmitate, ascorbyl dipalmitate,ascorbyl stearate, erythorbic acid, and sodium erythorbate.
Int. J. Toxicol.,18,1-26 (1999).
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